Browsing Health Sciences by Author "Aberg, Judith A."

Now showing items 1-3 of 3

    • Global pharmacovigilance for antiretroviral drugs : overcoming contrasting priorities 

      Bakare, Nyasha; Edwards, Ivor Ralph; Stergachis, Andy; Pal, Shanthi; Holmes, Charles B.; Lindquist, Marie; Duncombe, Chris; Dodoo, Alex; Novendstern, Joel; Nwokike, Jude; Kuchenbecker, Ricardo de Souza; Aberg, Judith A.; Miller, Veronica; Strobos, Jur (2011) [Journal article]

    • Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1 

      Ackerman, Peter; Thompson, Melanie; Molina, Jean-Michel; Aberg, Judith A.; Cassetti, Isabel; Kozal, Michael; Castagna, Antonella; Martins, Marcelo; Ramgopal, Moti; Sprinz, Eduardo; Treviño-Pérez, Sandra; Streinu-Cercel, Adrian; Latiff, Gulam H.; Pialoux, Gilles; Kumar, Princy N.; Wang, Marcia; Chabria, Shiven; Pierce, Amy; Llamoso, Cyril; Lataillade, Max (2021) [Journal article]
      Objectives: The aim of this study was to understand how demographic and treatment-related factors impact responses to fostemsavir-based regimens. Design: BRIGHTE is an ongoing phase 3 study evaluating twice-daily fostemsavir ...

    • Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1 

      Aberg, Judith A.; Shepherd, Bronagh; Wang, Marcia; Madruga, José V.; Urbina, Fernando Mendo; Katlama, Christine; Schrader, Shannon; Eron, Joseph J.; Kumar, Princy N.; Sprinz, Eduardo; Gartland, Margaret; Chabria, Shiven; Clark, Andrew; Pierce, Amy; Lataillade, Max; Tenorio, Allan R. (2023) [Journal article]
      Introduction: Efficacy and safety of the attachment inhibitor fostemsavir + optimized background therapy (OBT) were evaluated through 48 and 96 weeks in the phase 3 BRIGHTE trial in heavily treatment-experienced (HTE) ...